Clinical trial · no report yet · Phase 2
STOPNET
Cessation of Somatostatin Analogues After PRRT in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours
- NCT06345079 ↗
- Recruiting
- Australasian Gastro-Intestinal Trials Group
- 9 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 5 | |
| X threads | 3 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- A Randomised Study of Cessation of Somatostatin Analogues After Peptide Receptor Radionuclide Therapy in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours (STOPNET)
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Neuroendocrine Tumors
- Interventions
- Cessation of somatostatin analogues; Continuation of somatostatin analogues
- Arms
- Continue SSA · Active comparator
- Cease SSA · Experimental
- Enrollment
- 78 (estimated)
- Primary outcomes
- 20-month progression free survival rate after PRRT
- Assess the barriers which would impede the feasibility of a subsequent phase 3 trial
- Sponsor
- Australasian Gastro-Intestinal Trials Group with Canadian Cancer Trials Group
- Start
- Oct 14, 2024
- Primary completion
- Sep 2027 (estimated)
- Results posted
- No
- Registry record
- NCT06345079 · updated Sep 10, 2026